Icotyde-Icotrokinra Hydrochloride
Icotyde is a prescription medication indicated for the treatment of moderate-to-severe plaque psoriasis in patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Unlike topical treatments, Icotyde is intended for patients requiring systemic intervention, helping manage widespread or treatment-resistant disease. It works by […]
Lynavoy-Linerixibat
Lynavoy (linerixibat) is a prescription medication used in adults to treat cholestatic pruritus associated with primary biliary cholangitis (PBC), a chronic liver disease marked by bile acid buildup and persistent itching. Unlike conventional symptomatic treatments, Lynavoy works by inhibiting the ileal bile acid transporter (IBAT) in the intestine, reducing bile acid reabsorption and promoting their […]
Lifyorli-Relacorilant
Lifyorli (relacorilant) is a prescription medication used in combination with chemotherapy to treat advanced ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone prior treatments. Unlike conventional therapies, Lifyorli works as a selective glucocorticoid receptor antagonist, helping reduce tumor resistance and enhancing the effectiveness of chemotherapy. Advanced cancers often present challenges such […]
Myrbetriq-Mirabegron
Myrbetriq (mirabegron) is a prescription medication used in adults to manage overactive bladder (OAB), a condition characterized by urgency, increased frequency of urination, and urge-related leakage. Unlike traditional antimuscarinic therapies, Myrbetriq works through a β3-adrenergic pathway, helping relax the bladder’s smooth muscle during the storage phase. This allows the bladder to hold more urine and […]
Avlayah-Tividenofusp Alfa-Eknm
Avlayah is a prescription intravenous therapy used to treat neurological manifestations of Hunter syndrome (MPS II), a rare genetic disorder caused by enzyme deficiency leading to harmful substrate accumulation. Unlike traditional enzyme replacement therapies, Avlayah is designed to cross the blood–brain barrier, allowing delivery of the functional enzyme to both the body and the brain, […]
Redemplo-Plozasiran
Redemplo (plozasiran) is a targeted therapy approved for the treatment of familial chylomicronemia syndrome (FCS) in adults, in combination with a strict low-fat diet. FCS is a rare genetic lipid disorder in which the body cannot properly break down fats, leading to extremely high triglyceride levels and recurrent episodes of acute pancreatitis. Redemplo is designed […]
Loargys-Pegzilarginase-Nbln
Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment. Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping […]
Bysanti-Milsaperidone
Bysanti (milsaperidone) is an FDA-approved atypical antipsychotic indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. As an oral therapy, Bysanti is designed to modulate key neurotransmitter pathways, particularly dopamine and serotonin receptor activity, which play a central role […]
Yuviwel-Navepegritide
Yuviwel (navepegritide) is an FDA-approved C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia who have open epiphyses. Achondroplasia is a rare genetic skeletal disorder characterized by impaired endochondral bone growth due to overactive FGFR3 signaling, resulting in disproportionate short stature and associated […]
Keytruda Qlex-Pembrolizumab And Berahyaluronidase Alfa-Pmph
Keytruda Qlex is an FDA-approved subcutaneous formulation of Keytruda developed by Merck & Co. It contains the active immunotherapy molecule pembrolizumab, a PD-1 immune checkpoint inhibitor, combined with berahyaluronidase alfa, an enzyme that enables rapid subcutaneous delivery. Unlike the traditional intravenous (IV) infusion of Keytruda administered over 30 minutes, Keytruda Qlex is given as a […]
